Clinical Research Directory
Browse clinical research sites, groups, and studies.
Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock
Sponsor: Wake Forest University Health Sciences
Summary
Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.
Official title: Mechanistic Assessment of Norepinephrine TheRapy vs. Angiotensin-II in Septic Shock (MANTRA) Grant Submission- Dysfunctional Renin-Angiotensin System in Septic Shock
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
78
Start Date
2026-05
Completion Date
2028-08
Last Updated
2026-03-31
Healthy Volunteers
No
Conditions
Interventions
Angiotensin II
randomized to receive Angiotensin II continuous infusion for up to 48 hours
Norepinephrine
randomized to receive Norepinephrine continuous infusion for up to 48 hours
Locations (2)
Massachusetts General Hospital-Harvard
Boston, Massachusetts, United States
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States